MarketResearchReports.Biz presents this most up-to-date research on " Frontier Pharma: Versatile Innovation in Oncology - Identifying and Commercializing Versatile First-in-Class Innovation "
Innovations in technology have led to the growth of the global oncology market. Innovations such as the development of first-in-class products, the growing opportunities for biologic products, and regulatory policies have propelled the oncology market in many ways. The availability of reimbursement policies have also boosted the development of and innovations in first-in-class products. The rising number of products in the pipeline, especially in the pharmaceutical industry are expected to boost the market for oncology, predicts a new report added to the database of MarketResearchReports.biz.
The report, titled “Frontier Pharma: Versatile Innovation In Oncology - Identifying And Commercializing Versatile First-In-Class Innovation,” highlights the oncology pipeline on the basis of molecular target, molecule type, and phase. The research also briefs readers about various co-development deals among key companies. As per the findings of the report, mergers and acquisitions, and co-development deals will help the startup companies and key players to introduce new products in the global market.
With 6,484 products in the pipeline across oncology indications, this is predicted to be the biggest therapy area pipeline among all therapy areas. The oncology therapy area consists of a varied range of indications, covering all tissues and sites in the human body. These indications are known to be fatal if not treated in time. They are also the second-leading reason for deaths in many developing nations. In the global pharmaceutical industry, there are approximately 2,084 first-in-class oncology products in the development stage.
The research highlights the changing trends in oncology across many regions. As per the findings of the report, molecule type variation shifted away from the small molecules, and its dominance shifted from 94% across all marketed products to 49% across the pipeline. The report also states that over a period of time, there have been significant changes registered in inhibitors of the receptor tyrosine kinases, signal transduction proteins, and their ligands. There have been changing trends in the drugs directed towards cancer antigens. The research also studies some of the promising first-in-class targets such as FGFR3, telomerase reverse transcriptase, and HER3.
The report briefs readers about the current commercial and clinical landscape by taking into consideration diagnosis, pathogenesis, treatment options, and prognosis. The study further identifies various commercial opportunities present in the field of oncology by considering the changing trends in co-development deals and licensing deals for all products.
Various therapies and treatment options are also studied in the report by the analysts. Therapies such as epidemiology, etiology, prognosis and disease staging, and pathophysiology are analyzed in the report. After analyzing various therapy areas, the report then diverts its focus towards analyzing treatment options such as chemotherapy, surgery and radiation therapy, targeted therapies, and hormonal therapies.